Racemates revisited: heterochiral assemblies and the example of dl-thalidomide

References

• Allen FH, Trotter J. (1971). Crystal and molecular structure of thalidomide, N-(α-glutarimido)-phthalimide. J Chem Soc [B] 1073–1079.
   Google Scholar
• Andelman D. (1989). Chiral discrimination and phase transitions in Langmuir monolayers. J Am Chem Soc 111:6536–6544.
   Web of Science ®Google Scholar
• Barrett AM, Cullum VA. (1968). The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br J Pharmacol 34:43–55.
   PubMed Web of Science ®Google Scholar
• Berthelot M, Jungfleisch E. (1874). Recherches sur l’isomérie symétrique et sur les quatre acides tartriques. C R Acad Sci 78:711–716.
   Google Scholar
• Berthelot M, Jungfleisch E. (1875). Recherches sur l’isomérie symétrique et sur les quatre acides tartriques. Ann Chim Phys [5th série] 4:147–154.
   Google Scholar
• Bruni G. (1904). Racemism. Atti Accad Naz Lincei Rend 13:373–381.
   Google Scholar
• Bruni G, Finzi F. (1904). Racemism. Atti Accad Naz Lincei Rend 13:349–355.
   Google Scholar
• Bruni G, Podoa M. (1902a). Sull’esistenza di corpi racemi in soluzione; nota preliminare. Gazz Chim Ital 32:503–509.
   Google Scholar
• Bruni G, Podoa M. (1902b). Sull’esistenza di corpi racemi in soluzione. Atti Accad Naz Lincei Rend 11:212–217.
   Google Scholar
• Bryson FFS, Logie J. (1913). On the constitution of the mercury green line (λ = 5461 Å u) Phil Mag [Series 6] 26:366–375.
   Google Scholar
• Byk A. (1904a). Zur Frage der Spaltbarkeit von Razemverbindung durch zirkular-polarisiertes Licht, ein Beitrag zur primären Entstehung optisch-aktiver Substanz. Z Phys Chem 49:641–687.
   Google Scholar
• Byk A. (1904b). Zur Frage der Spaltbarkeit von Racemverbindungen durch zirkular-polarisiertes Licht, ein Beitrag zur primären Entstehung optisch-aktiver Substanz. Ber Deut Chem Ges 37:4696–4700.
   Google Scholar
• Byk A. (1905). Zur Frage der Spaltbarkeit von Racemverbindungen durch zirkular-polarisiertes Licht, ein Beitrag zur primären Entstehung optisch-aktiver Substanz. Chem Zentr 76:318–319.
   Google Scholar
• Cotton A. (1896). Recherches sur l’absorption et la dispersion de la lumière par les milieux doués du pouvoir rotatoire. Ann Chim Phys [7th série] 8:347–432.
   Google Scholar
• Cotton A. (1929). Sur la synthèse asymétrique et sur l’existence en solution des composés racémiques. C R Acad Sci 189:1211–1213.
   Google Scholar
• Cundy KC, Crooks PA. (1983). Unexpected phenomenon in the high-performance liquid chromatographic analysis of racemic 14C-labelled nicotine: separation of enantiomers in a totally achiral system. J Chromatogr 281:17–33.
   Web of Science ®Google Scholar
• Dunlop JH, Evans DF, Gillard RD, Wilkinson G. (1966). Optically active coordination compounds. VI. Stereoselective effects in alkaline tartrate-complexes of transition metals. J Chem Soc [A] 1260–1264.
   Google Scholar
• Dunstan AE, Thole FB. (1908). The relation between viscosity and chemical constitution. Part II. The existence of racemic compounds in the liquid state. J Chem Soc Trans 93:1815–1821.
   Google Scholar
• Dunstan AE, Thole FB. (1910). The existence of racemic compounds in solution. J Chem Soc Trans 97:1249–1256.
   Google Scholar
• Eliel EL. (1962). Stereochemistry of Carbon Compounds. New York: McGraw-Hill, pp. 44–45.
   Google Scholar
• Eliel EL, Wilen SH, Doyle MP. (2001). Basic Organic Stereochemistry. New York: Wiley-Interscience, pp. 107–111.
   Google Scholar
• Ellis GP. (1966). Modern Textbook of Organic Chemistry. London: Butterworths, pp. 251–253.
   Google Scholar
• Eriksson T, Björkman S, Roth B, Fyge A, Höglund P. (1998). Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 10:223–228.
   PubMed Web of Science ®Google Scholar
• Fabro S, Smith RL, Williams RT. (1967). Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215:296.
   PubMed Web of Science ®Google Scholar
• Fabro SE, Schumacher H, Smith RL, Williams RT. (1963). [Metabolism of thalidomide. I. The spontaneous hydrolysis of thalidomide]. Boll Soc Ital Biol Sper 39:1921–1925.
   PubMedGoogle Scholar
• Finar IL. (1959). Organic Chemistry: Stereochemistry and the Chemistry of Natural Products. London: Longmans, Green, Vol. 2, 2nd edn, p. 57.
   Google Scholar
• Furberg S. (1965). Structural relationship between thalidomide and nucleosides. Acta Chem Scand 19:1266–1267.
   PubMedGoogle Scholar
• Furberg S, Petersen CS. (1965). The crystal structure of N-(α-glutarimido)-4-bromophthalimide. Acta Chem Scand 19:253–254.
   Google Scholar
• Gheorghiu TD. (1929). Sur l’absorption des tartrates de cuivre gauche et de leur mélange. C R Acad Sci 189:1260–1262.
   Google Scholar
• Gheorghiu TD. (1933). The use of gas photoelectric cells in photometric measurements. Appl Ann Phys 20:133–242.
   Google Scholar
• Hague D. (1969). Some Biochemical Aspects of Thalidomide Toxicity. Ph.D. Thesis, University of London, England, UK.
   Google Scholar
• Hague D, Smith R. (1988). Enigmatic properties of (±)thalidomide: an example of a stable racemic compound. Br J Clin Pharmacol 26:623.
   Web of Science ®Google Scholar
• Harger MJP. (1976). Nuclear-magnetic resonance non-equivalence of the enantiomers of optically active samples of phosphinic acids. J Chem Soc Chem Commun 555–556.
   Google Scholar
• Harger MJP. (1977). Proton magnetic resonance non-equivalence of the enantiomers of alkylphenylphosphinic amides. J Chem Soc Perkin Trans 2:1882–1887.
   Google Scholar
• Harger MJP. (1978a). Chemical shift non-equivalence of enantiomers in the proton magnetic resonance spectra of partly resolved phosphinothioic acids. J Chem Soc Perkin Trans 2:326–331.
   Google Scholar
• Harger MJP. (1978b). Proton magnetic resonance spectra of chiral phosphorus esters: chemical shift non-equivalence of enantiomers induced by optically active phosphinothioic acids. Tet Lett 19:2927–2928.
   Google Scholar
• Heilbronner E, Dunitz JD. (1993). Reflections on Symmetry in Chemistry ... and Elsewhere. Basel: Verlag HCA, p. 114.
   Google Scholar
• Horeau A, Guetté JP. (1974). Interactions diastereoisomeres d’antipodes en phase liquide. Tetrahedron 30:1923–1931.
   Web of Science ®Google Scholar
• Huang SH, Bai ZW, Feng JW. (2009). Chiral self-discrimination of the enantiomers of alpha-phenylethylamine derivatives in proton NMR. Magn Reson Chem 47:423–427.
   PubMed Web of Science ®Google Scholar
• Jönsson NA. (1972a). Chemical structure and teratogenic properties. 3. A review of available data on structure–activity relationships and mechanism of action of thalidomide analogues. Acta Pharm Suec 9:521–542.
   PubMedGoogle Scholar
• Jönsson NA. (1972b). Chemical structure and teratogenic properties. IV. An outline of a chemical hypothesis for the teratogenic action of thalidomide. Acta Pharm Suec 9:543–562.
   PubMedGoogle Scholar
• Kabachnik MI, Mastryukova TA, Fedin EI, Vaisberg MS, Morozov LL, Petrovskii PV, Shipov AE. (1976). An NMR study of optical isomers in solution. Tetrahedron 32:1719–1728.
   Web of Science ®Google Scholar
• Kabachnik MI, Mastryukova TA, Fedin EI, Vaisberg MS, Morozov LL, Petrovskii PV, Shipov AE. (1978). Optical isomers in solution investigated by nuclear magnetic resonance. Usp Khim 47:1541–1564; Russ Chem Rev 47:821–834.
   Google Scholar
• Kagan K. (1979). Organic Stereochemistry. London: Edward Arnold, p. 96.
   Google Scholar
• Knobloch J, Shaughnessy JD Jr, Rüther U. (2007). Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J 21:1410–1421.
   PubMed Web of Science ®Google Scholar
• Knoche B, Blaschke G. (1994). Investigations on the in vitro racemization of thalidomide by high-performance liquid chromatography. J Chromatogr 666:235–240.
   Web of Science ®Google Scholar
• Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD. (2006). Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab 7:677–685.
   PubMed Web of Science ®Google Scholar
• Liu ST, Hurwitz A. (1978). Effect of enantiomeric purity on solubility determination of dexclamol hydrochloride. J Pharm Sci 67:636–638.
   PubMed Web of Science ®Google Scholar
• Nean SH, Shinwari MK, Hellmuth EW. (1993). Melting point phase diagrams of free base and hydrochloride salts of bevantolol, pindalol and propranolol. Int J Pharm 99:303–310.
   Google Scholar
• Pasteur ML. (1850). Recherches sur les propriétés spécifiques des deux acides qui composent l’acide racémique. Ann Chim Phys [3rd série] 28:56–99.
   Google Scholar
• Peterson CS. (1969). The crystal structure of N-(α-glutarimido)-4-bromophthalimide. Acta Chem Scand 23:2389–2402.
   Google Scholar
• Pirkle WH, Hoover DJ. (1982). NMR chiral solvating agents. In: Allinger NL, Eliel EL, Wilen SH, eds. Topics in Stereochemistry. New York: Wiley-Interscience, Vol. 13, pp. 263–331.
   Google Scholar
• Reist M, Carrupt PA, Francotte E, Testa B. (1998). Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem Res Toxicol 11:1521–1528.
   PubMed Web of Science ®Google Scholar
• Repta AJ, Baltezor MJ, Bansal PC. (1976). Utilization of an enantiomer as a solution to a pharmaceutical problem: application to solubilization of 1,2-di(4-piperazine-2,6-dione)propane. J Pharm Sci 65:238–242.
   PubMed Web of Science ®Google Scholar
• Roozeboom HWB. (1899). Loslichkeit und Schmelzpunkt als Kriterien für racemische Verbindungen, pseudoracemische Mischkrystalle und inaktive Konglomerate. Z Phys Chem 28:494–517.
   Google Scholar
• Schumacher H, Smith RL, Williams RT. (1965a). The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol Chemother 25:324–337.
   PubMed Web of Science ®Google Scholar
• Schumacher H, Smith RL, Williams RT. (1965b). The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol Chemother 25:338–351.
   PubMed Web of Science ®Google Scholar
• Shealy YF, Opliger CE, Montgomery JA. (1965). d- and l-thalidomide. Chem Ind 24:1030–1031.
   PubMedGoogle Scholar
• Shealy YF, Opliger CE, Montgomery JA. (1968). Synthesis of d- and l-thalidomide and related studies. J Pharm Sci 57:757–764.
   PubMed Web of Science ®Google Scholar
• Singh BK, Amma MKP. (1953). Studies on the nature of the racemic modifications of optically active compounds in the solid state. Part X. σ-,m-,p-Chloroanilino-camphor-β-sulphonates (d and dl) and camphor-β-sulphonyl-σ-,m-,p-chlorophenylamides (d and dl). Proc Math Sci 38:502–515.
   Google Scholar
• Smith RL. (2008). Racemic heterochiral assemblies: a novel aspect of chirality: biological implications. Eur J Drug Metab Pharmacokinet 33:10–11.
   Google Scholar
• Stephens TD. (1988). Proposed mechanisms of action in thalidomide embryopathy. Teratology 38:229–239.
   PubMedGoogle Scholar
• Stephens TD, Bunde CJ, Fillmore BJ. (2000). Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59:1489–1499.
   PubMed Web of Science ®Google Scholar
• Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N. (2009). Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci USA 106:8573–8578.
   PubMed Web of Science ®Google Scholar
• Williams RT, Schumacher H, Fabro S, Smith RL (1965). The chemistry and metabolism of thalidomide. In: Robson JM, Sullivan FM, Smith RL, eds. Embryopathic Activity of Drugs. London: JA Churchill, pp. 167–193.
   Google Scholar
• Williams T, Pitcher RG, Bommer P, Gutzwiller J, Usokovic M. (1969). Diastereomeric solute–solute interactions of enantiomers in achiral solvents. Nonequivalence of the nuclear magnetic resonance spectra of racemic and optically active dihydroquinine. J Am Chem Soc 91:1871–1872.
   Web of Science ®Google Scholar